EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry

Trung M Dang, Alessandro Invernizzi, Vuong Nguyen, Yohei Hashimoto, Francesco Romano iD, Mariano Cozzi iD, Jennifer Arnold, James Wong, Hemal Mehta, Samantha Fraser-Bell, Richard Barry, Daniel Barthelmes und 2 weitere

Clinical & Experimental Ophthalmology · 2025

DOI: 10.1111/ceo.70033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Trung M Dang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Eye Clinic Albury Wodonga, Albury, New South Wales, Australia. Hauptthemen laut MEDLINE: Registries, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Wet Macular Degeneration. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We analysed 12‐month real‐world outcomes of treatment of eyes with neovascular age‐related macular degeneration switched to brolucizumab from a first‐generation VEGF inhibitor to determine whether switching chronically active eyes that required frequent treatment improved control of the disease safely with fewer injections.

Methods

Retrospective analysis of Australian and Italian data from the prospectively designed observational Fight Retinal Blindness! registry. We studied eyes that switched to brolucizumab and received at least two injections with 12 months of follow‐up.

Results

Of the 81 eligible eyes, the proportion of inactive lesions increased from 5% at baseline to 37% 12 months after switching to brolucizumab ( p < 0.001). Mean (95% CI) visual acuity (VA) was stable (0.6 [−1.5, 2.8] letters, p = 0.55), while median treatment intervals increased from 44 to 63 days ( p < 0.001). Nearly a third (30%) of eyes switched back to another VEGF inhibitor within 12 months. Eyes that stayed on brolucizumab had a significantly longer mean treatment interval at 12 months than eyes that switched off it (66.1 [Q1, Q3: 56, 91] vs. 49 [28, 63.2] days, p ≤ 0.001) while VA change and inactivation rates were similar. Intraocular inflammation (IOI) was recorded in 7 (9%) eyes receiving at least one injection of brolucizumab.

Conclusions

Eyes that switched from a first generation VEGF inhibitor to brolucizumab in routine clinical practice achieved a clinically significant extension of their treatment interval, with more than a third becoming inactive but with a relatively high rate of IOI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedWet Macular DegenerationBlindnessHumansRetrospective StudiesVisual AcuityMaleFemaleIntravitreal InjectionsAgedVascular Endothelial Growth Factor ATreatment OutcomeFollow-Up StudiesAged, 80 and overTomography, Optical CoherenceFluorescein AngiographyMiddle AgedAustraliaDrug Substitution

Stichwörter der Autor:innen

adverse eventsbrolucizumabneovascular macular degenerationobservational studiestreatmenttreatment outcomes

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor AbrolucizumabAntibodies, Monoclonal, HumanizedVEGFA protein, human

Autor:innen und Institutionen

  • Eye Clinic Albury Wodonga, Albury, New South Wales, Australia.
  • The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, Sydney, New South Wales, Australia.
  • Eye Clinic, Department of Biomedical and Clinical Science, Luigi Sacco Hospital, University of Milan, Milan, Italy.
  • Marsden Eye Specialists, Sydney, New South Wales, Australia.
  • Strathfield Retina Clinic, Sydney, New South Wales, Australia.
  • Department of Ophthalmology, Royal Free London NHS Foundation Trust, London, UK.

ORCID-Profile: Francesco Romano, Mariano Cozzi

Förderung

  • Novartis

Zitieren

APA

Dang, T. M., Invernizzi, A., Nguyen, V., Hashimoto, Y., Romano, F., Cozzi, M., Arnold, J., Wong, J., Mehta, H., Fraser-Bell, S., Barry, R., Barthelmes, D., Gillies, M., & Luckie, A. (2025). Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.70033

Vancouver

Dang TM, Invernizzi A, Nguyen V, Hashimoto Y, Romano F, Cozzi M, et al. Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.70033

BibTeX
@article{Dang2025,
  author = {Dang, Trung M and Invernizzi, Alessandro and Nguyen, Vuong and Hashimoto, Yohei and Romano, Francesco and Cozzi, Mariano and Arnold, Jennifer and Wong, James and Mehta, Hemal and Fraser-Bell, Samantha and Barry, Richard and Barthelmes, Daniel and Gillies, Mark and Luckie, Alan},
  title = {Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2025},
  doi = {10.1111/ceo.70033}
}
Kostenlos starten →